[go: up one dir, main page]

WO2005040195A3 - Formulation of exendins - Google Patents

Formulation of exendins Download PDF

Info

Publication number
WO2005040195A3
WO2005040195A3 PCT/US2004/035267 US2004035267W WO2005040195A3 WO 2005040195 A3 WO2005040195 A3 WO 2005040195A3 US 2004035267 W US2004035267 W US 2004035267W WO 2005040195 A3 WO2005040195 A3 WO 2005040195A3
Authority
WO
WIPO (PCT)
Prior art keywords
articles
exendins
methods
formulation
articles made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/035267
Other languages
French (fr)
Other versions
WO2005040195A2 (en
Inventor
Stephen C Rowe
Durga Annavajjula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azopax Therapeutics LLC
Original Assignee
Azopax Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azopax Therapeutics LLC filed Critical Azopax Therapeutics LLC
Publication of WO2005040195A2 publication Critical patent/WO2005040195A2/en
Publication of WO2005040195A3 publication Critical patent/WO2005040195A3/en
Priority to US11/410,269 priority Critical patent/US20070053954A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods and articles for the administration of exendins. These methods and articles provide for the controlled and sustained delivery of relatively large quantities of an exendin with a low burst effect. The articles made using the method of the invention have increased percentages (w/w) of macromer, increased crosslinking density, and reduced pore size in comparison to articles made using solution methods.
PCT/US2004/035267 2003-10-24 2004-10-22 Formulation of exendins Ceased WO2005040195A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/410,269 US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51429203P 2003-10-24 2003-10-24
US60/514,292 2003-10-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/410,269 Continuation-In-Part US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Publications (2)

Publication Number Publication Date
WO2005040195A2 WO2005040195A2 (en) 2005-05-06
WO2005040195A3 true WO2005040195A3 (en) 2005-09-15

Family

ID=34520189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035267 Ceased WO2005040195A2 (en) 2003-10-24 2004-10-22 Formulation of exendins

Country Status (1)

Country Link
WO (1) WO2005040195A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3524261T (en) 2005-08-19 2024-04-10 Amylin Pharmaceuticals, Llc Exendin for use in treating diabetes and reducing body weight
US20100234306A1 (en) * 2007-09-11 2010-09-16 Dorian Bevec Use of a peptide as a therapeutic agent
KR20100075438A (en) * 2007-09-11 2010-07-02 몬도바이오테크 래보래토리즈 아게 Use of a peptide as a therapeutic agent
EP2303313B1 (en) 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1999003454A1 (en) * 1997-07-18 1999-01-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6699504B2 (en) * 2000-01-28 2004-03-02 Pelias Technologies, Inc. Slow release protein polymers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1999003454A1 (en) * 1997-07-18 1999-01-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6699504B2 (en) * 2000-01-28 2004-03-02 Pelias Technologies, Inc. Slow release protein polymers

Also Published As

Publication number Publication date
WO2005040195A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
WO2005058537A3 (en) Medical devices and methods of making the same
WO2005048952A3 (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
WO2005099667A3 (en) Drug delivery compositions
WO2006042230A8 (en) Medical devices and methods of making the same
AU2003273259A1 (en) Drug cartridge assembly and method of manufacture
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
WO2003082247A3 (en) Drug microparticles
WO2006055603A3 (en) Injectable nanoparticulate olanzapine formulations
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO2004084950A3 (en) Cell targeting methods and compositions
WO2002030463A3 (en) Reduced-viscosity concentrated protein formulations
WO2004000389A3 (en) Rapidly dissolving micro-perforator for drug delivery and other applications
AU2003265929A1 (en) Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol)
WO2003011226A3 (en) Products and drug delivery vehicles
WO2005027794A3 (en) Medical devices
WO2005021022A3 (en) Stable formulations of peptides
WO2009083544A3 (en) Pdgf fusion proteins incorporated into fibrin foams
WO2006009987A3 (en) Dissolvable film composition
WO2007135461A3 (en) Pharmaceutical compositions comprising implitapide and methods of using same
WO2001070197A3 (en) Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
WO2005041873A3 (en) Formulation of exendin-4
PL1638535T3 (en) Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
WO2006014921A3 (en) Themes indicative of participants in persistent communication

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11410269

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11410269

Country of ref document: US